Two Drugs, One Stunning Myeloma Result

By pairing a BCMA-targeted T-cell engager with an anti-CD38 antibody, researchers achieved strikingly deep remissions and sharply reduced relapse risk in patients with relapsed myeloma. The results suggest this dual immune-directed strategy could challenge current treatment sequencing, including when to deploy engineered T-cell therapies.

Publication Details

Journal
Cancer Discovery
Published
2025-12-19
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0114
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Two Drugs, One Stunning Myeloma Result

Cancer Discovery
CAR-T cell therapy research
article

Two Drugs, One Stunning Myeloma Result

article en

Abstract

By pairing a BCMA-targeted T-cell engager with an anti-CD38 antibody, researchers achieved strikingly deep remissions and sharply reduced relapse risk in patients with relapsed myeloma. The results suggest this dual immune-directed strategy could challenge current treatment sequencing, including when to deploy engineered T-cell therapies.

Cancer DiscoveryVol. 16(2)
Zero hunger
Openalex Percentile: Top 32%
CAR-T cell therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Two Drugs, One Stunning Myeloma Result · Cancer Discovery (2025) | TGRS Research Map | TGRS